Progress in Cardiovascular Diseases Progress in Cardiovascular Diseases RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Safety and Efficacy of Transcatheter Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation
Atrial Fibrillation (AF) is associated with a substantial risk of thromboembolic stroke. Although long-term treatment with warfarin or the non-vitamin K oral anticoagulants can reduce this risk, such therapy is underutilized, and safe and consistent long-term treatment can be challenging. Transcatheter left atrial appendage (LAA) closure is an emerging alternative to long-term oral anticoagulation. Long-term follow-up of randomized clinical trials demonstrate that Watchman LAA closure provides significant reductions in hemorrhagic stroke, cardiovascular death, and all-cause mortality compared with continued warfarin therap...
Source: Progress in Cardiovascular Diseases - January 12, 2018 Category: Cardiology Authors: Matthew J. Price Source Type: research

Selection of P2Y12 Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome
The P2Y12 receptor plays a critical role in the amplification of platelet aggregation in response to various agonists and stable thrombus generation at the site of vascular injury leading to deleterious ischemic complications. Therefore, treatment with a P2Y12 receptor blocker is a major effective strategy to prevent ischemic complications in high-risk patients with acute coronary syndrome (ACS) and patients undergoing percutaneous coronary intervention (PCI). The determination of optimal platelet inhibition is based on maximizing antithrombotic properties while minimizing bleeding risk and is critically dependent on indiv...
Source: Progress in Cardiovascular Diseases - January 12, 2018 Category: Cardiology Authors: Udaya S. Tantry, Eliano P. Navarese, Aung Myat, Paul A. Gurbel Source Type: research

Anticoagulation in Acute Coronary Syndrome-State of the Art
Early intravenous anticoagulation is the corner stone treatment of patients admitted with an acute coronary syndrome: it antagonizes the ongoing coronary thrombosis and facilitates the percutaneous coronary intervention, hence a reduction of mortality and acute stent thrombosis. Unfractionated heparin, enoxaparin, bivalirudin and fondaparinux have been extensively studied in large randomized control trials and meta-analyses with the same objective: reducing the ischemic burden without hiking hemorrhagic events. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - January 12, 2018 Category: Cardiology Authors: Michel Zeitouni, Mathieu Kerneis, Tarek Nafee, Jean-Philippe Collet, Johanne Silvain, Gilles Montalescot Source Type: research

Comparison of Anticoagulant Therapy for Atrial Fibrillation - Novel Oral Anticoagulants Versus Vitamin K Antagonists
In patients with non-valvular atrial fibrillation (NVAF), oral anticoagulation is important for prevention of stroke and systemic embolism (SE). While Vitamin K antagonists (VKAs) have historically been the standard of care, these medications are limited by numerous food and drug interactions with onerous requirements for frequent monitoring and dose adjustments. Over the past decade, several novel oral anticoagulants (NOACs) have been developed to directly inhibit factor IIa/thrombin (dabigatran) or activated factor X (apixaban, rivaroxaban, edoxaban). (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - January 12, 2018 Category: Cardiology Authors: Sean T. Chen, Manesh R. Patel Source Type: research

The timing of P2Y12 inhibitor initiation in the treatment of ACS? Does the evidence exist in this era?
The majority of acute coronary syndromes (ACS) are well characterized as a consequence of plaque rupture and subsequent thrombosis. Antiplatelet agents targeting inhibition of P2Y12 receptors on the platelets have shown to reduce future risk of cardiovascular events in this patient population. However, the timing of initiation of these agents, in particular, in patients managed with invasive strategy with percutaneous coronary interventions (PCI) is debatable. The data supporting pretreatment with antiplatelet agents prior to PCI in ACS patients dates to trials performed>15  years ago, wherein the time to PCI was>5  da...
Source: Progress in Cardiovascular Diseases - January 12, 2018 Category: Cardiology Authors: Harsh Golwala, Deepak L. Bhatt Source Type: research

Safety and efficacy of Transcatheter left atrial appendage closure for stroke prevention in patients with atrial fibrillation
Atrial fibrillation (AF) is associated with a substantial risk of thromboembolic stroke. Although long-term treatment with warfarin or the non-vitamin K oral anticoagulants can reduce this risk, such therapy is underutilized, and safe and consistent long-term treatment can be challenging. Transcatheter left atrial appendage (LAA) closure is an emerging alternative to long-term oral anticoagulation. Long-term follow-up of randomized clinical trials demonstrate that Watchman LAA closure provides significant reductions in hemorrhagic stroke, cardiovascular death, and all-cause mortality compared with continued warfarin therap...
Source: Progress in Cardiovascular Diseases - January 12, 2018 Category: Cardiology Authors: Matthew J. Price Source Type: research

Selection of P2Y12 inhibitor in percutaneous coronary intervention and/or acute coronary syndrome
The P2Y12 receptor plays a critical role in the amplification of platelet aggregation in response to various agonists and stable thrombus generation at the site of vascular injury leading to deleterious ischemic complications. Therefore, treatment with a P2Y12 receptor blocker is a major effective strategy to prevent ischemic complications in high -risk patients with acute coronary syndrome (ACS) and patients undergoing percutaneous coronary intervention (PCI). The determination of optimal platelet inhibition is based on maximizing antithrombotic properties while minimizing bleeding risk and is critically dependent on indi...
Source: Progress in Cardiovascular Diseases - January 12, 2018 Category: Cardiology Authors: Udaya Tantry, Eliano P. Navarese, Aung Myat, Paul Gurbel Source Type: research

Anticoagulation in acute coronary syndrome-state of the art
Early intravenous anticoagulation is the corner stone treatment of patients admitted with an acute coronary syndrome: it antagonizes the ongoing coronary thrombosis and facilitates the percutaneous coronary intervention, hence a reduction of mortality and acute stent thrombosis. Unfractionated heparin, enoxaparin, bivalirudin and fondaparinux have been extensively studied in large randomized control trials and meta-analyses with the same objective: reducing the ischemic burden without hiking hemorrhagic events. (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - January 12, 2018 Category: Cardiology Authors: Michel Zeitouni, Mathieu Kerneis, Tarek Nafee, Jean-Philippe Collet, Johanne Silvain, Gilles Montalescot Source Type: research

Comparison of anticoagulant therapy for atrial fibrillation - novel oral anticoagulants versus vitamin K antagonists
In patients with non-valvular atrial fibrillation (NVAF), oral anticoagulation is important for prevention of stroke and systemic embolism (SE). While Vitamin K antagonists (VKAs) have historically been the standard of care, these medications are limited by numerous food and drug interactions with onerous requirements for frequent monitoring and dose adjustments. Over the past decade, several novel oral anticoagulants (NOACs) have been developed to directly inhibit factor IIa/thrombin (dabigatran) or activated factor X (apixaban, rivaroxaban, edoxaban). (Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - January 12, 2018 Category: Cardiology Authors: Sean T. Chen, Manesh R. Patel Source Type: research

Masthead
(Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - January 1, 2018 Category: Cardiology Source Type: research

Table of contents
(Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - January 1, 2018 Category: Cardiology Source Type: research

List of recent issues
(Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - January 1, 2018 Category: Cardiology Source Type: research

Editorial Board
(Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - January 1, 2018 Category: Cardiology Source Type: research

Masthead
(Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - January 1, 2018 Category: Cardiology Source Type: research

Table of contents
(Source: Progress in Cardiovascular Diseases)
Source: Progress in Cardiovascular Diseases - January 1, 2018 Category: Cardiology Source Type: research